ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Resistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance that do not imply mutations in BCR/ABL have been also described. In the present rep...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Clara I Aceves-Luquero, Anupriya Agarwal, Juan L Callejas-Valera, Laura Arias-González, Azucena Esparís-Ogando, Luis del Peso Ovalle, Itxaso Bellón-Echeverria, Miguel A de la Cruz-Morcillo, Eva M Galán Moya, Inmaculada Moreno Gimeno, Juan C Gómez, Michael W Deininger, Atanasio Pandiella, Ricardo Sánchez Prieto
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2009
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/3dff57472bb442969456148bb3804193
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/3dff57472bb442969456148bb3804193

Ejemplares similares